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Abstract
Background: The clinical correlations and significance of subnormal CD4 levels in HIV-negative patients with TB are unclear.
We have determined CD4 cell levels longitudinally during anti-tuberculosis treatment (ATT) in patients, with and without
HIV co-infection, and their associations with clinical variables.
Method: Adults diagnosed with TB (maximum duration of ATT for 2 weeks, and with no history of antiretroviral therapy
(ART) in HIV-positive subjects) were included consecutively in eight out-patient clinics in Ethiopia. Healthy individuals were
recruited for comparison at one of the study health centers. Data on patient characteristics and physical findings were
collected by trained nurses following a structured questionnaire at inclusion and on follow-up visits at 2 and 6 months. In
parallel, peripheral blood CD4 cell levels were determined. The evolution of CD4 cell levels during ATT was assessed, and the
association between clinical characteristics and low CD4 cell levels at baseline was investigated using regression analysis.
Results: In total, 1116 TB patients were included (307 HIV-infected). Among 809 HIV-negative patients, 200 (25%) had
subnormal CD4 cell counts (,500 cells/mm3), with ,350 cells/mm3 in 82 (10%) individuals. CD4 cell levels increased
significantly during the course of ATT in both HIV+ and HIV- TB-patients, but did not reach the levels in healthy subjects
(median 896 cells/mm3). Sputum smear status, signs of wasting (low mid upper arm circumference (MUAC)), and bedridden
state were significantly associated with low CD4 cell counts.
Conclusion: A high proportion of Ethiopian TB patients have subnormal CD4 cell counts before starting treatment. Low CD4
cell levels are associated with smear positive disease and signs of wasting. The continuous increase of CD4 cell counts
during the course of ATT suggest a reversible impact of active TB on CD4 cell homeostasis, which may be considered in
interpretation of CD4 cell counts in HIV/TB co-infected subjects.
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Introduction
The majority of persons co-infected with TB and HIV (79% of
1.1 million patients in 2011) live in sub-Saharan Africa [1]. HIV-
infected individuals have a high risk of developing active TB
following infection, and also have increased mortality. Initiation of
ART during the course of ATT has been shown to reduce
mortality in co-infected persons, especially in those who are
severely immunosuppressed [2–4], and is recommended in current
WHO guidelines [5].
Absolute CD4 cell levels are the main markers for disease
severity in patients with HIV, as well as the best markers yet for
disease progression [6]. The time for initiation of ART is based on
these levels, also for patients with concomitant TB [5]. The
reference range of CD4 cell counts is broad, and these counts can
be affected by several factors [7]. Some studies have observed a
lower range of CD4 cell counts in apparently healthy subjects in
regions of sub-Saharan Africa than the reference range in
Caucasian populations [8,9], suggesting the existence of geo-
graphical variations. Furthermore, low CD4 cell counts in HIV-
negative patients with TB have been described from different
settings, suggesting that TB by itself could have an impact on CD4
cell homeostasis; however, the mechanism, clinical correlations or
significance of this phenomenon are not well understood [10–12].
We have recently found that low CD4 cell count strata are
strongly correlated to signs of wasting among HIV-positive
PLOS ONE | www.plosone.org 1 December 2013 | Volume 8 | Issue 12 | e83270
Ethiopian adults with TB (unpublished data). In order to estimate
the contribution of TB per se to the associations between clinical
parameters and CD4 cell counts, we have prospectively followed
these variables in TB-patients, with and without HIV co-infection
recruited in Ethiopian health centers.
Materials and Methods
Ethics statement
All subjects provided written informed consent prior to inclusion
into the study. No interventions interfering with standard care
were done during the study period, with the exception of CD4 cell
count analysis of HIV-/TB individuals. The study was approved
by the National Ethics Review Committee at the Ministry of
Science and Technology of Ethiopia and by the Ethical Review
Board at Lund University, Sweden.
Study design and setting
This prospective cohort study was conducted in outpatient TB
clinics in the Oromia region, Ethiopia. Adult patients with TB
were recruited at six health centers and two hospitals between
September 2010 and September 2012. A reference group of
healthy HIV-negative subjects were recruited consecutively from a
voluntary HIV counseling and testing (VCT) facility in one of the
health centers.
Diagnosis and treatment of patients with TB
Patients were diagnosed with TB according to Ethiopian
National Guidelines [13]. Three sputum smears were obtained
from each patient. Smear positive pulmonary TB was defined by
the detection of acid-fast bacilli (AFB) in at least one out of three
sputum smears. The diagnosis of smear negative pulmonary TB
required two series of negative sputum smears, non-response to
broad-spectrum antibiotics, as well as clinical presentation and
chest X-ray compatible with pulmonary TB. For a diagnosis of
peripheral lymphnode TB, fine-needle aspirate cytology consistent
with the diagnosis was required. Other forms of extrapulmonary
TB were diagnosed using targeted investigations, depending on
organ manifestation.
ATT was provided as directly observed treatment (DOTS) with
daily visits to the clinic during the intensive phase treatment. From
September to December 2010, an eight-month course of
rifampicin, isoniazid, pyrazinamide and ethambutol was given
for two months, followed by isoniazid and ethambutol for 6
months. This regimen was then changed to a standard short-
course regimen (two-month treatment with all four drugs with a
four-month continuation phase of rifampicin and isoniazid).
HIV testing
HIV testing is recommended for all patients with confirmed or
suspected TB in Ethiopia, and is performed using rapid tests by
TB clinic staff through provider-initiated testing. During the study
period, KHB tests (Kehua Bio-engineering Co, Shanghai, China)
were used for screening. Positive results with this test were
confirmed with Statpack (HIV 1/2 Stat-Pak, Chembio Diagnostic
Systems, New York, USA); if this test showed a negative result,
further testing was done with Unigold (Uni-Gold TM HIV,
Trinity Biotech, Wicklow, Ireland). In case of a positive test,
patients were referred to an ART clinic in the same facility for
enrolment in HIV care and consideration of ART initiation.
Methods
The following inclusion criteria were applied: age 18 years or
older, TB diagnosed according to national guidelines, residence in
the clinic catchment area and consent to HIV testing. Exclusion
criteria were: having received ATT for more than 2 weeks for the
current episode of TB at the time of inclusion, previous ATT
within the preceding 6 months, or ART of any duration. TB-clinic
nurses, who received detailed and repeated training by the
research group members on the study protocol, performed all
study investigations.
The study protocol included questions on disease history and
symptoms (bedridden state, hospitalization, cough, dyspnea, fever,
weight loss, anorexia, lymph node enlargement, skin rash, diarrhea
and odynophagia). The physical examinations focused on findings
potentially associated with immunosuppression, including con-
junctival pallor, oral candidiasis, oral hairy leukoplakia (OHL),
gingivitis, cervical lymphadenopathy, skin rash (without further
specification) and herpes zoster scar. MUAC and BMI were used
as markers for wasting and were collected, using scales and wall
mounted measuring sticks for BMI calculation and dedicated
measuring bands for measurement of MUAC provided to the
health centers.
Follow-up examination was performed following the same
procedure after 2 and 6 months of ATT. Treatment outcome was
defined according to WHO based national guideline criteria, i.e.
treatment completion, cure, death, treatment failure, default and
transfer out [5]. The date of ART initiation was noted for those HIV
patients who started such treatment during the follow-up period.
Consenting healthy individuals were recruited at a VCT clinic
located in one of the study health centers. These subjects were
required to be 18 years of age or older, have a negative HIV rapid
test and have no known chronic illness or any symptoms suggestive
of TB or acute disease. They were recruited and interviewed by a
trained peer counselor using a structured questionnaire, with
measurement of BMI and MUAC.
Blood samples were obtained for CD4 cell count analysis at
baseline, and were repeated at 2 and 6 months for all TB-patients.
CD4 cell count flow cytometry was performed at two central
laboratories (Adama regional laboratory and Bishoftu hospital
laboratory) using FACSCount and FACSCaliber (Becton Dick-
inson). Regular monitoring and external quality assurance tests of
the machines were performed regularly. For the purpose of this
study, HIV testing was repeated after 6 months in patients testing
negative for HIV at baseline if initial CD4 cell counts were below
350 cells/mm3.
Data collection and statistical analysis
Data was collected on paper forms and was entered into a
Microsoft ExcelH database and crosschecked before transfer to
IBM SPSSH V.20, which was used as a base for all statistical
analysis. Baseline characteristics were reported as frequencies,
percentages or median values. Wilcoxon signed rank test was used
for statistical test for significance between observations at different
time points. Two threshold levels were used for definition of low
CD4 cell counts in HIV-negative TB patients (HIV-/TB)
subnormal CD4 cell counts (below 500 cells/mm3; since this is
the lower normal reference value), and CD4 lymphocytopenia
(below 350 cells/mm3;the current recommended threshold for
starting ART in HIV+ patients).
A univariate analysis of all variables was performed. For this
analysis, BMI and MUAC were categorized according to the
median of the HIV-negative patients. Variables with a p-value of
less than 0.3 were entered into a multivariable regression analysis,
adjusting for age and gender.
For TB patients, we analyzed development of CD4 levels during
ATT. For HIV-positive TB patients (HIV+/TB), only those who
did not start ART during the follow-up period were included for this
Clinical Features of TB-Associated CD4-Lymphopenia
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analysis to avoid the effect of ART on CD4 cell count evolution. A
change of at least 50 cells/mm3 between observation time points
was used to define increasing or decreasing CD4 cell counts.
Results
Baseline characteristics
Out of 2135 patients registered in the clinics during the study
period, 1116 (52%) were included, whereas 1019 had at least one
exclusion criterion. Among these, 225 (22%) were under 18 years
of age, 127 (12%) did not consent to participation, 60 (6%) did not
consent to HIV-testing, 94 (9%) resided outside the catchment
area, and 309 (30%) had received more than 2 weeks of ATT at
the time of screening for eligibility. Among HIV-positive subjects,
284 were on ART at the time of TB diagnosis. Seventeen
participants were excluded since they did not provide blood for
baseline CD4 cell count. Furthermore, for 81 HIV-/TB patients,
follow up CD4 samples at either 2 or 6 months were missing and
those patients were only included in the baseline analysis.
Of the 1116 patients included, 307 (28%) were HIV positive
and 166 (54%) of these started ART during the 6-month follow up
period. Baseline characteristics of the study participants are
presented in table 1. The HIV positive and negative subjects were
comparable in distribution of age, gender, residence and
occupational distribution. There was a non-significant increased
frequency of smear positive pulmonary TB among HIV-/TB
patients, and conversely a higher frequency of smear negative
pulmonary disease in HIV+/TB patients. The healthy individuals
tended to be younger and have rural residence, but the gender
distribution was similar.
Among HIV+/TB patients the median CD4 cell count was
173 cells/mm3 (IQR 95-336). The median CD4 cell count was
lower in the HIV-/TB patients compared to reference subjects,
671 cells/mm3 (IQR 500–883.5) vs. 896 cells/mm3 (IQR 700–
1083). Two-hundred HIV-/TB patients (25%) had CD4 cell
counts below 500 cells/mm3, and 82 (10%) had CD4 cell counts
lower than 350 cells/mm3.
Evolution of CD4 cell counts during ATT
Among 472 HIV-/TB patients with follow-up results for CD4
cell counts during ATT, the median counts increased from
688 cells/mm3 (IQR 497–917) to 753 cells/mm3 (figure 1). Patients
without follow-up CD4 cell count results (n = 337) had similar
median baseline CD4 cell counts (666 cells/mm3; IQR 508–859).
The rise in CD4 cell counts was even more pronounced in
HIV-/TB patients with low baseline CD4 cell counts; in HIV-/TB
patients with CD4 cell counts less than 500 cells/mm3 these
counts increased from a median of 380 to 550 cells/mm3 after 6
months. In contrast to the other subgroups (figure 1), these patients
also manifested a significant increase throughout treatment (both
between baseline and 2 month follow up as well as between 2 and
6 month follow up). For HIV+/TB patients the increase was
significant from baseline to either 2 month or 6-month follow up.
Although the majority of HIV-/TB patients with CD4 cell
counts below 500 cells/mm3 had increasing CD4 cell levels during
treatment (n = 87), 24 of these subjects did not show this pattern,
and in 8 patients these levels even decreased. The characteristics of
these subgroups of HIV-/TB patients are presented in table 2 and 3.
No clear differences in the distribution of such characteristics were
observed between these subgroups.
For HIV+/TB patients who did not start ART (n= 71), overall
median CD4 cell counts increased, but for these subjects the
pattern was more heterogeneous than that found in HIV-/TB
patients. In 35 cases CD4 cell counts had increased after 6 months,
while these counts had decreased for 17 patients, and remained at
similar levels for 19 patients. HIV+/TB patients with increasing
CD4 cell counts had lower baseline levels (188 cells/mm3) than
those with decreasing CD4 cell counts (505 cells/mm3).
Clinical characteristics of HIV-/TB patients with low CD4
cell counts
The correlation between clinical parameters and low CD4 cell
counts at baseline (less than 500 cells/mm3 or less than 350 cells/
mm3) is presented in detail in table 4. Patients with baseline CD4
cell counts below 500 cells/mm3 were significantly more likely to









Median Age (years; IQR) 28 (22–28) 32 (28–40) 29 (22 – 42) 23 (20 – 28)
Male gender, n (%) 724 (51.2) 156 (50.8) 432 (53.4) 136 (54.4)
Occupation Sales and services 96 (8.6) 35 (11.4) 61 (7.5) 19 (6.6)
Manual labor 335 (30) 113 (36.8) 222 (27.4) 216 (74.5)
Agriculture 208 (18.6) 43 (14.0) 165 (20.4) 53 (18.3)
Unemployed 477 (42.7) 116 (37.8) 361 (44.6) 2 (0.7)
Residence, n (%) Urban 943 (84.7) 274 (89.5) 669 (82.9) 182 (65.5)
Rural 170 (15.3) 32 (10.4) 138 (17.1) 96 (34.5)
Type of TB, n (%)* Smear positive 405 (36.3) 99 (32.2) 306 (37.8) -
Smear negative 310 (27.8) 94 (30.6) 216 (26.7) -
Lymph node TB 296 (26.5) 87 (28.3) 209 (25.8) -
Other location of TB 125 (11.2) 36 (11.7) 89 (11.0) -
Previous TB 47 (3.3) 7 (2.3) 40 (4.9) -
Median CD4 cell count (IQR) 639 (376 – 890.3) 173 (95 – 336) 671 (500 – 883.5) 897 (700 – 1083)
Median CD4 percentage (IQR) 35 (25–41) 12 (8 – 18) 37 (30.9 – 43.0) 37 (33 – 43)
*20 patients had both a diagnosis of pulmonary and extrapulmonary TB.
doi:10.1371/journal.pone.0083270.t001
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have smear positive pulmonary TB (adjusted OR 1.6, IQR 1.2-2-
3). Reversely, the prevalence of smear negative pulmonary TB was
lower in this group (adjusted OR 0.6, IQR 0.4–0.9). A similar,
although not statistically significant, relationship was observed for
patients with CD4 cell counts below 350 cells/mm3.
MUAC, being a surrogate marker for wasting, was significantly
associated with low CD4 cell counts in multivariate analysis, with a
more than twofold chance of having a MUAC below 22 cm with
baseline CD4 cell counts below 350 cells/mm3 (adjusted OR 2.2,
IQR 1.3–3.6). There was a trend between lower BMI and
decreasing CD4 cell counts, although this did not reach statistical
significance. Furthermore, patients with a history of bedridden
state during their current illness were more likely to have low CD4
cell counts (OR 2.3, IQR 1.3–4.0).
Figure 1. Evolution of CD4 cell counts in HIV negative and positive patients with TB during treatment for TB. The figure shows median
CD4 levels and the bars represent IQR. Only patients with follow up CD4 are included in this analysis, and for the control group only baseline CD4 was
measured. For HIV+ patients, only patients who did not start ART and had follow up CD4 were included (n = 71).
doi:10.1371/journal.pone.0083270.g001
Table 2. Characteristics of HIV-/TB patients and CD4 cell count of less than 500, divided by either increase, decrease or stagnant
CD4 cell count after 6 months ATT.
Increase after 6 month (n =87) Decrease after 6 month (n =8) No change after 6 month (n =24)
Baseline 2 Month 6 month Baseline 2 Month 6 month Baseline 2 Month 6 month
Age 29 36 24
Male gender, n (%) 54 (62.1) 7 (87.5) 14 (58.3)
Smear positive TB, n (%) 39 (44.8) 3 (37.5) 9 (37.5)
Smear negative TB, n (%) 15 (17.2) 3 (37.5) 6 (25)
Lymph node TB, n (%) 23 (26.4) 0 6 (25)
Other location of TB, n (%) 10 (11.5) 2 (25) 3 (12.5)
Median BMI kg/height2 18.4 19.1 19.8 17.7 19.0 18.8 17.2 18.4 18.7
Median MUAC (cm) 21.5 22.0 23.0 21.0 21.8 22.0 20.0 22.0 22.5
Median CD4 cells/mm3 372 557 605 424.5 448 342.5 400 435 406
Median Percentage 29.6 - 32.4 32.0 - 37.0 33.5 - 30.5
*Increase or decrease defined as .50 cells/mm3. Only patients who had follow up CD4 cell counts were included in the analysis
doi:10.1371/journal.pone.0083270.t002
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Outcome of ATT
Thirteen deaths were observed among HIV-/TB patients.
These subjects did not show significant differences in clinical
features or CD4 cell counts as compared to other patients; their
median BMI and MUAC values were slightly lower (18.1 kg/m2
and 21 cm, respectively) as well as their CD4 cell counts
(559 cells/mm3).
Discussion
In this cohort of Ethiopian adults with TB the prevalence of low
CD4 cell counts among HIV-negative persons before initiation of
Table 3. Characteristics of HIV+/TB patients not starting ART divided by either increase, decrease or stagnant CD4 cell count after
6 months ATT.
Increase after 6 month (n=35) Decrease after 6 month (n=19) No change after 6 month (n=17)
Baseline 2 month 6 month Baseline 2 month 6 month Baseline 2 month 6 month
Age 35 (28–38) 31 32
Male gender, n (%) 19 (54.3) 8 (42.1) 8 (47.1)
Smear positive pulmonary TB, n (%) 9 (25.7) 7 (36.8) 4 (23.5)
Smear negative pulmonary TB, n (%) 13 (37.1) 7 (36.8) 5 (29.4)
Lymph node TB, n (%) 5 (14.3) 6 (31.6) 6 (35.3)
Other location of TB, n (%) 5 (14.3) 2 (10.5) 2 (11.8)
Median BMI kg/height2 17.8 18.5 19.6 18.5 19.7 19.6 18.4 18.8 19.9
Median MUAC (cm) 20 21 22.5 22 23 23 21 22 24
Median CD4 cells/mm3 188 288 417 505 505 407 243 235 249
Median Percentage 11.0 15.0 23.0 18.0 13.0 12.0
Increase or decrease defined as .50 cells/mm3. Only patients who had follow up CD4 cell counts were included in the analysis
doi:10.1371/journal.pone.0083270.t003
Table 4. Correlation of clinical parameters to CD4 cell cut off levels in HIV-/TB patients.
CD4 cell count ,500 cells/mm3, n=200 CD4 cell count ,350 cells/mm3, n =82
Frequency all
HIV-/TB patients Frequency OR unadjusted OR adjusted* Frequency OR unadjusted OR adjusted*
Previous TB 40 3 0.2 (0.1–0.8) 0.2 (0.1–0.7) 2 0.5 (0.1–1.9) 0.3 (0.1–1.9)
Smear positive PTB 306 94 1.7 (1.2–2.3) 1.6 (1.2–2.3) 36 1.3 (0.8–2.1) 1.3 (0.8–2.0)
Smear negative PTB 216 41 0.6 (0.4–0.9) 0.6 (0.4–0.9) 20 0.9 (0.5–1.5) 0.8 (0.5–1.4)
Lymphnode TB 209 42 0.7 (0.5–1.0) 0.8 (0.5–1.2) 18 0.8 (0.5–1.4) 0.9 (0.5–1.5)
Cervical lymph node enlargement 120 18 0.5 (0.3–0.8) 0.6 (0.3–1.0) 10 0.8 (0.4–1.5) 0.9 (0.5–1.8)
Cough 509 142 1.6 (1.1–2.3) 1.4 (1.0–2.0) 58 1.5 (0.9–2.4) 1.3 (0.8–2.2)
Bloodstained sputum 162 49 1.4 (1.0–2.1) 1.3 (0.9–1.9) 24 1.8 (1.1–2.9) 1.6 (1.0–2.8)
Shortness of breath 342 92 1.2 (0.9–1.7) 1.2 (0.9–1.6) 38 1.2 (0.7–1.9) 1.1 (0.7–1.8)
Fever 618 159 1.3 (0.9–1.9) 1.3 (0.9–1.9) 67 1.4 (0.8–2.6) 1.4 (0.8–2.6)
Night sweats 627 161 1.2 (0.8–1.9) 1.2 (0.8–1.8) 68 1.4 (0.8–2.6) 1.4 (0.8–2.5)
Conjunctival pallor 93 27 1.3 (0.8–2.1) 1.1 (0.7–1.9) 13 1.5 (0.8–2.9) 1.4 (0.7–2.7)
Diarrhea 34 11 1.5 (0.7–3.1) 1.6 (0.7–3.3) 3 0.9 (0.3–2.8) 0.9 (0.3–2.9)
Diarrhea, recurrent 29 13 2.6 (1.2–5.5) 2.3 (1.1–5.0) 6 2.4 (1.0–6.1) 2.2 (0.9–5.6)
Loss of appetite 558 143 1.2 (0.8–1.7) 1.2 (0.8–1.7) 62 1.4 (0.9–2.4) 1.4 (0.9–2.5)
Odynophagia 102 27 1.1 (0.7–1.8) 1.1 (0.7–1.8) 15 1.6 (0.9–3.0) 1.6 (0.9–3.0)
Significant weight loss 554 144 1.3 (0.9–1.8) 1.2 (0.8–1.7) 65 1.8 (1.0–3.2) 1.7 (1.0–3.1)
Lower than median BMI
(,18.5 kg/m2)
388 105 1.3 (0.9–1.8) 1.2 (0.8–1.6) 41 1.1 (0.7–1.7) 1.0 (0.6–1.6)
Lower than median MUAC (,22 cm) 400 125 2.0 (1.5–2.8) 1.9 (1.4–2.7) 55 2.3 (1.4–3.7) 2.2 (1.3–3.6)
Hospitalized 15 5 1.5 (0.5–4.5) 1.7 (0.6–5.1) 3 2.3 (0.6–8.3) 2.5 (0.7–9.3)
Bedridden state 102 41 2.3 (1.5–3.6) 2.1 (1.4–3.3) 19 2.3 (1.3–4.1) 2.3 (1.3–4.0)
*Adjusted for age and gender.Only parameters with significance of less than 0.3 in univariate analysis are present in the table. Variables that did not reach this level of
significance were: other location of TB, gingivitis, herpes zoster, oral candidiasis, oral hairy leukoplakia and skin rash.
doi:10.1371/journal.pone.0083270.t004
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ATT was substantial; 25% had CD4 cell counts below 500 cells/
mm3 and 10% had CD4 cell counts lower than 350 cells/mm3,
which is the currently recommended lower threshold level for
starting ART in HIV-positive subjects. By correlating CD4 cell
strata with clinical variables, we could show that low CD4 cell
counts are associated with TB disease severity, such as sputum
smear positivity, lower MUAC and bedridden state.
Low CD4 cell levels in HIV-/TB patients have been reported
previously; in a study on hospitalized TB patients from Senegal,
Kony et. al. found CD4 cell counts below 300 cells/mm3 in 14%
[11]. Fifty-three (7%) HIV-/TB cases from our cohort had CD4
cell levels below this threshold level. In line with our findings on
associations with clinical severity reported here, the lower
prevalence of CD4 lymphocytopenia in our population could be
related to more advanced disease in hospitalized subjects. In
contrast to previous findings from factory workers in Wonji, a
district in the vicinity of our study area in Ethiopia [9], we did not
find subnormal CD4 cell counts among healthy individuals.
The continuous increase of CD4 cell counts during treatment
for TB strongly suggests that TB per se contributes to subnormal
CD4 cell levels in peripheral blood. Similar findings have been
reported by other researchers in HIV-/TB patients both in the
African setting and in other geographical locations [11,14–17];
however, the reasons for this phenomenon, or its clinical
significance, are not well understood.
In parallel with increasing median CD4 cell counts during
ATT, we observed continuous improvements in signs of wasting
(both BMI and MUAC), which implies that CD4 cell depletion
and wasting are related to similar underlying factors in TB.
Associations between signs of wasting and CD4 cell levels have
been explored previously, with discrepant results. In Argentinian
HIV-/TB patients, Pilheu et al found lower CD4 cell count in
subjects reporting significant weight loss (.20%) than in those
with better general condition [17]. In contrast, other researchers
failed to show an association between BMI and CD4 cell counts in
HIV-/TB patients (14, 16). In a study on CD4 cell levels among
healthy Ethiopian factory workers, Abuye et al reported lower
BMI in subjects with subnormal CD4 cell counts [8].
For the investigation of correlations between CD4 cell counts
and clinical variables we used both BMI and MUAC as markers
for wasting and malnutrition. In multiple regression analysis,
MUAC ,22 cm was correlated with low CD4 cell counts (both
below 500 and 350 cells/mm3) in HIV-/TB patients. BMI did not
turn out to be significant, although there was a trend towards
lower CD4 cell count with decreasing BMI. This suggests that
MUAC may be a more suitable marker for wasting in this patient
group than BMI. In a study from Guinea Bissau MUAC showed a
stronger correlation to mortality in HIV+/TB patients than BMI
[18].
Several studies have shown a relationship between malnutrition
and mortality in TB patients [19–21]. We did not, however, find
associations between ATT outcome and low baseline CD4 cell
counts in our HIV-/TB patients, probably due to the low
frequency of adverse outcomes. There was also no clear
association between signs of wasting and poor outcome.
Interestingly, we have previously found relationships between
CD4 cell strata and wasting (particularly MUAC) in HIV+/TB
patients from this cohort (unpublished data), a finding that might
be useful to identify subjects with severe immune suppression in
settings without access to CD4 cell testing. The fact that similar
associations between CD4 cell counts and wasting exist in HIV-/
TB suggests that TB may contribute to the wasting syndrome
commonly found in co-infected patients, as well as contributing to
CD4 cell depletion. Our finding that CD4 cell counts increased
during ATT in HIV+/TB patients not initiating ART further
supports this, though the mechanism of the interaction between
wasting and low CD4 cell count remains a matter of debate
[22,23].
In contrast to HIV+/TB, HIV-/TB patients with low CD4 cell
counts had normal CD4 cell percentage, suggesting that the
observed decreases in absolute CD4 cell counts are related to
peripheral blood lymphocytopenia. Possible explanations for this
could be pooling of T-cells at the site of infection [24,25], a direct
cytokine mediated suppressive effect on the production of
peripheral lymphocytes [26], or effects related to hypermetabolism
and malnutrition secondary to TB infection [23,27].
The recovery rate of CD4 cell counts in HIV-/TB patients with
subnormal baseline levels was slow and continuous, and did not
reach the levels found in healthy individuals from the same
geographical area even at the completion of ATT. This is in
agreement with findings from HIV+/TB patients, showing an
impact of TB on CD4 cell counts for several years after completion
of ATT [28].
In a study from Tanzania, an increase was demonstrated
between baseline and 2 months. Between baseline and 5 month
follow up CD4 was unchanged for those not receiving ART [14].
Increasing CD4 cell levels were also observed in HIV+/TB
patients not starting ART in our cohort. When divided into
subgroups of those with increasing and decreasing CD4 cell count,
the result was heterogeneous. This may be expected since HIV in
itself lowers CD4 cell counts, thus cancelling a potential effect of
ATT on CD4 cell count in some patients. The number of HIV+/
TB patients not starting ART during ATT was low (n = 71), which
limits the interpretation of these findings. However, our data
suggest that severe TB (as measured by the degree of wasting) can
contribute to CD4 lymphocytopenia in co-infected subjects, and
that it may be partly reversed by ATT.
Our study design has allowed us to correlate clinical variables
with CD4 cell counts longtitudinally during ATT in patients with
TB, both with and without HIV co-infection. This study also has
some limitations. Firstly, TB diagnosis was based on Ethiopian
guidelines, and did not include microbiological confirmation other
than smear microscopy. Consequently, some subjects with smear-
negative pulmonary TB and extrapulmonary disease may have
had diagnoses other than TB. We were unable to estimate this
proportion; however, in a previous study, 78% of patients
diagnosed with lymph node TB according to the Ethiopian
Guidelines were found to have positive TB cultures from lymph
node aspirates [29], suggesting that the fraction of participants
with diagnoses other than TB was small. Furthermore, the
methods used for TB diagnosis among our patients reflect the
actual situation in most resource-limited settings. We cannot
exclude the existence of other factors not screened for in this study
that may have had an impact on CD4 cell counts. Finally, HIV
diagnosis relied on rapid tests (evaluated by WHO in 2004 [30]),
which could potentially have produced false negative results from
subjects in HIV seroconversion phase. For this purpose, we
repeated HIV testing in patients with CD4 cell counts below
350 cells/mm3 at the end of ATT. No HIV seroconversions were
detected.
In conclusion, we found a high proportion of CD4 cell
lymphocytopenia in Ethiopian HIV-negative adults diagnosed
with TB. These levels increased during ATT, both in HIV-
negative patients and in HIV+/TB patients not initiating ART,
indicating an impact of TB on CD4 cell homeostasis. Decreased
CD4 cell counts was associated with clinical markers of advanced
TB disease, such as sputum smear positivity, low MUAC and
Clinical Features of TB-Associated CD4-Lymphopenia
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bedridden state. These findings suggest that similar factors cause
wasting and CD4 cell depletion in peripheral blood in TB.
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